Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
    Elstein, Deborahy
    Belmatoug, Nadia
    Deegan, Patrick
    Goker-Alpan, Ozlem
    Hughes, Derralynn A.
    Schwartz, Ida Vanessa D.
    Weinreb, Neal
    Bonner, Nicola
    Panter, Charlotte
    Fountain, Donna
    Lenny, Andrew
    Longworth, Louise
    Miller, Rachael
    Shah, Koonal
    Schenk, Jorn
    Sen, Rohini
    Zimran, Ari
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [32] Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa
    Kimball, Alexa B.
    Sundaram, Murali
    Banderas, Benjamin
    Foley, Catherine
    Shields, Alan L.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (02) : 152 - 164
  • [33] Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
    Goswami, Pushpendra
    Oliva, Esther N.
    Ionova, Tatyana
    Else, Roger
    Kell, Jonathan
    Fielding, Adele K.
    Jennings, Daniel M.
    Karakantza, Marina
    Al-Ismail, Saad
    Collins, Graham P.
    McConnell, Stewart
    Langton, Catherine
    Salek, Sam
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [34] OHIP-TMDs: a patient-reported outcome measure for temporomandibular disorders
    Yule, Pamela L.
    Durham, Justin
    Playford, Hannah
    Moufti, Mohammed Adel
    Steele, Jimmy
    Steen, Nick
    Wassell, Robert W.
    Ohrbach, Richard
    COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 2015, 43 (05) : 461 - 470
  • [35] The French-Canadian validation of a disease-specific, patient-reported outcome measure for lupus
    Bourre-Tessier, J.
    Clarke, A. E.
    Kosinski, M.
    Mikolaitis-Preuss, R. A.
    Bernatsky, S.
    Block, J. A.
    Jolly, M.
    LUPUS, 2014, 23 (14) : 1452 - 1459
  • [36] Short form development for oral health patient-reported outcome evaluation in children and adolescents
    Liu, Honghu
    Hays, Ron
    Wang, Yan
    Marcus, Marvin
    Maida, Carl
    Shen, Jie
    Xiong, Di
    Lee, Steve
    Spolsky, Vladimir
    Coulter, Ian
    Crall, James
    QUALITY OF LIFE RESEARCH, 2018, 27 (06) : 1599 - 1611
  • [37] Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain
    Giraldo, Pilar
    Camprodon, Maria
    Alcolea, Paloma Cerro
    Gras-Colomer, Elena
    Ibarretxe, Daiana
    Lakhwani, Sunil
    Mora, Elvira
    Calderon, Maria Purificacion Velasco
    Morales-Conejo, Montserrat
    MEDICINA CLINICA, 2024, 163 (09): : 449 - 457
  • [38] Development and validation of the patient-reported outcome scale for chronic kidney disease
    Yu Shi
    Shi Pu
    Hongmei Peng
    Yu Luo
    International Urology and Nephrology, 2024, 56 : 653 - 665
  • [39] Development and content validity of a hemodialysis symptom patient-reported outcome measure
    Flythe, Jennifer E.
    Dorough, Adeline
    Narendra, Julia H.
    Wingard, Rebecca L.
    Dalrymple, Lorien S.
    DeWalt, Darren A.
    QUALITY OF LIFE RESEARCH, 2019, 28 (01) : 253 - 265
  • [40] First Phase Development of a Patient-reported Outcome Measure for Midface Oncology
    Yung, Amanda E.
    Luong, Jason
    Crouch, Gareth
    Hong, Angela M.
    Ananda, Arjuna
    Taylor, Simon
    Kotronakis, Ilias
    Low, Tsu-Hui
    Elliott, Michael S.
    Mcbride, Kate
    Rutherford, Claudia
    Clark, Jonathan R.
    Ch'ng, Sydney
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2024, 12 (03)